2005
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) initiated a communication to physicians regarding the clinical performance of its VENTAK PRIZM® 2 DR Model 1861 implantable defibrillator....
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that it has received Investigational Device Exemption (IDE) conditional approval from the U.S. Food and Drug Administration...
Guidant Shareholders Overwhelmingly Approve Acquisition Agreement with Johnson & Johnson
Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) announced that at a special meeting of shareholders held today in Indianapolis, Guidant shareholders overwhelmingly approved the agreement...
New Brunswick, N.J., and Indianapolis, Ind. - Johnson & Johnson and Guidant Corporation today announced that they have been notified, as anticipated, that the European Commission has decided to...
Company Completes Several Merger-Related Milestones During Quarter Sales of products other than worldwide coronary stents were $838 million, up 10 percent Worldwide implantable defibrillator...